The exponential Organ-on-a-chip Market growth is fundamentally fueled by two powerful external pressures: the prohibitive cost of drug attrition in the pharmaceutical industry and a definitive shift in regulatory acceptance. The failure of drug candidates in Phase II and III clinical trials—often due to undisclosed human toxicity or poor efficacy—costs billions of dollars per...

The organ-on-a-chip market is gaining traction, with its share expanding significantly due to advancements in biomedical engineering and increased demand for more accurate drug testing models. These microfluidic devices replicate human organ functions, providing a more reliable alternative to traditional cell culture and animal testing methods. With the global healthcare sector emphasizing...